Surgical Access Combined With Systematically Administered Antibiotics in the Treatment of Peri-implantitis

• Status: Recruiting
• Trial end date: 2023-12-05
• Target enrollment: 0
• Participant gender: All

Summary

This randomized clinical trial evaluates the clinical and microbiological (microbial complexes and changes in the diversity of the submucosal biofilm) effects of MTZ+AMX as adjuncts to anti-infectious surgical treatment plus Er: YAG in the treatment of peri-implantitis.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Guarulhos
• Collaborator: ITI Foundation
• Treatments: Amoxicillin; Metronidazole

Criteria

Inclusion Criteria:

• 18-70 years of age;

• in general good health,

• at least one dental implant in function for at least one year with untreated peri-implantitis defined as: presence of bleeding and/or suppuration on gentle probing, probing depths (PD) ≥ 6mm, and bone levels ≥3mm apical of the most coronal portion of the intraosseous part of the implant.

Exclusion Criteria:

• subjects with ≥6 sites with PD ≥5mm;

• individuals that received periodontal treatment within three months prior to entering the study;

• inability to perform proper supramucosal and supragingival plaque control (e.g., due to improper restoration design or lack of skills);

• poorly adapted implant-supported restoration;

• diabetes;

• pregnancy;

• nursing;

• history of allergies to metronidazole and/or amoxicillin, or any other ingredient of oral care products;

• alcohol or drug abuse;

• any systemic diseases that could affect post-operative healing or that required antibiotic premedication for routine dental therapy;

• long-term use of mouthrinses;

• anti-inflammatory medications;

• any other drug that could interfere with the study outcomes within three months prior to entering the study;

• use of antibiotics within six months prior to entering the study.